Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEMD NASDAQ:HIND NASDAQ:QNRX NASDAQ:SURG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEMDAethlon Medical$2.34+1.8%$2.12$1.36▼$35.20$3.68M1.549,328 shs183,728 shsHINDVyome$2.06-2.0%$2.38$1.75▼$33.16$14.44M1.38610,340 shs16,190 shsQNRXQuoin Pharmaceuticals$6.32-0.8%$7.14$5.20▼$41.80$11.25M1.6178,349 shs10,547 shsSURGSurgePays$0.54-4.1%$0.74$0.46▼$3.45$13.44M0.32353,997 shs21,293 shsThe 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEMDAethlon Medical-3.36%+3.14%+10.05%+3.14%-92.43%HINDVyome-4.55%+3.45%-0.47%-23.36%+209,999,900.00%QNRXQuoin Pharmaceuticals-0.93%-1.70%+0.79%-10.78%+3.92%SURGSurgePays+2.65%-7.13%-20.30%-43.68%-78.63%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEMDAethlon Medical$2.34+1.8%$2.12$1.36▼$35.20$3.68M1.549,328 shs183,728 shsHINDVyome$2.06-2.0%$2.38$1.75▼$33.16$14.44M1.38610,340 shs16,190 shsQNRXQuoin Pharmaceuticals$6.32-0.8%$7.14$5.20▼$41.80$11.25M1.6178,349 shs10,547 shsSURGSurgePays$0.54-4.1%$0.74$0.46▼$3.45$13.44M0.32353,997 shs21,293 shsThe 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEMDAethlon Medical-3.36%+3.14%+10.05%+3.14%-92.43%HINDVyome-4.55%+3.45%-0.47%-23.36%+209,999,900.00%QNRXQuoin Pharmaceuticals-0.93%-1.70%+0.79%-10.78%+3.92%SURGSurgePays+2.65%-7.13%-20.30%-43.68%-78.63%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEMDAethlon Medical 1.50ReduceN/AN/AHINDVyome 2.40Hold$15.00629.22% UpsideQNRXQuoin Pharmaceuticals 1.00SellN/AN/ASURGSurgePays 2.00Hold$5.00834.58% UpsideCurrent Analyst Ratings BreakdownLatest AEMD, HIND, SURG, and QNRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026HINDVyome Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/4/2026HINDVyome Litchfield Hills ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy5/1/2026HINDVyome Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)4/22/2026QNRXQuoin Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026AEMDAethlon Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/17/2026SURGSurgePays Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$9.75 ➝ $5.002/23/2026SURGSurgePays Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEMDAethlon MedicalN/AN/AN/AN/A$25.52 per shareN/AHINDVyome$320K45.13N/AN/A$0.67 per share3.07QNRXQuoin PharmaceuticalsN/AN/AN/AN/A$15.64 per shareN/ASURGSurgePays$56.96M0.24N/AN/A($0.66) per share-0.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEMDAethlon Medical-$13.39M-$14.69N/AN/AN/AN/A-219.39%-164.33%6/25/2026 (Estimated)HINDVyome-$10.26M-$125.20N/AN/AN/A-270.58%-279.99%-142.04%N/AQNRXQuoin Pharmaceuticals-$15.81M-$34.29N/AN/AN/AN/A-535.00%-223.99%N/ASURGSurgePays-$36.07M-$1.81N/A8.92N/A-63.32%-967.32%-241.91%5/12/2026 (Estimated)Latest AEMD, HIND, SURG, and QNRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q4 2025SURGSurgePays-$0.16N/AN/AN/A$15.50 millionN/A5/7/2026Q1 2026QNRXQuoin Pharmaceuticals-$2.17-$1.77+$0.40-$1.77N/AN/A3/27/2026Q4 2025QNRXQuoin Pharmaceuticals-$6.42-$14.80-$8.38-$1.74N/AN/A2/12/2026Q3 2026AEMDAethlon Medical-$2.01-$2.45-$0.44-$2.45N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAEMDAethlon MedicalN/AN/AN/AN/AN/AHINDVyomeN/AN/AN/AN/AN/AQNRXQuoin PharmaceuticalsN/AN/AN/AN/AN/ASURGSurgePaysN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEMDAethlon MedicalN/A5.685.68HINDVyomeN/A1.991.99QNRXQuoin PharmaceuticalsN/A3.613.61SURGSurgePaysN/A0.380.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEMDAethlon Medical1.99%HINDVyome22.06%QNRXQuoin Pharmaceuticals8.63%SURGSurgePays6.94%Insider OwnershipCompanyInsider OwnershipAEMDAethlon Medical0.71%HINDVyome33.00%QNRXQuoin Pharmaceuticals13.46%SURGSurgePays30.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEMDAethlon Medical101.57 million1.56 millionNo DataHINDVyome507.02 million4.70 millionN/AQNRXQuoin Pharmaceuticals41.80 million1.56 millionNot OptionableSURGSurgePays4025.12 million17.46 millionOptionableAEMD, HIND, SURG, and QNRX HeadlinesRecent News About These CompaniesHow The SurgePays (SURG) Story Is Shifting As Analysts Rework Valuation AssumptionsMay 3, 2026 | finance.yahoo.comF5 Networks (FFIV) Beats Q2 Earnings and Revenue EstimatesApril 28, 2026 | zacks.comSurgePays Advances AI Decisioning Platform Focused on Increasing Revenue Per User Across the Subprime MarketApril 21, 2026 | globenewswire.comSurgePays, Inc. Q4 2025 Earnings Call SummaryApril 16, 2026 | finance.yahoo.comSurgePays, Inc. (NASDAQ:SURG) Q4 2025 Earnings Call TranscriptApril 16, 2026 | insidermonkey.comSurgePays (SURG) Q4 2025 Earnings Call TranscriptApril 15, 2026 | fool.comSurgePays, Inc.: SurgePays Reports Full Year 2025 Results and Highlights Scalable Growth Model with Improved Cost Structure Entering 2026April 15, 2026 | finanznachrichten.deSurgepays Inc (SURG) Q4 2025 Earnings Call Highlights: Navigating Challenges and Capitalizing ...April 15, 2026 | finance.yahoo.comSurgePays (SURG) stock falls 30% overnight: What's going on?April 15, 2026 | msn.comSurgePays, Inc. (SURG) Q4 2025 Earnings Call TranscriptApril 14, 2026 | seekingalpha.comSurgePays Reports Full Year 2025 Results and Highlights Scalable Growth Model with Improved Cost Structure Entering 2026April 14, 2026 | globenewswire.comSurgePays Delays Filing of Annual 10-K ReportApril 10, 2026 | theglobeandmail.comSurgePays Launches Stored Value and Loyalty Platform Across Retail NetworkApril 2, 2026 | markets.businessinsider.comSurgePays to Host Fourth Quarter and Full Year 2025 Earnings Conference CallMarch 31, 2026 | globenewswire.comSurgePays Launches Nationwide LinkUp Mobile Promotion to Accelerate Subscriber GrowthMarch 17, 2026 | globenewswire.comLinkUp Mobile Surpasses 100,000 Subscriber Lines, Reaching Key Prepaid Wireless MilestoneFebruary 2, 2026 | globenewswire.comR. F. Lafferty & Co., Inc. Serves as Sole Book Runner in Closing of $2.5 Million Public Offering for SurgePaysJanuary 29, 2026 | desmoinesregister.comDSurgePays Announces Closing of $2.5 Million Public OfferingJanuary 26, 2026 | markets.businessinsider.comSurgePays, Inc. Announces Underwritten Public Offering of Common Stock and Pre-Funded WarrantsJanuary 20, 2026 | quiverquant.comQSurgePays Outsources Finances to Mack, Names Pullano Interim CFOJanuary 15, 2026 | marketwatch.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026Alphabet’s Earnings Didn’t Just Beat—They Changed the StoryBy Ryan Hasson | April 30, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 20265 Stocks to Buy in May Before the Next AI Surge HitsBy Thomas Hughes | May 1, 2026GPU Prices Are Surging—3 Ways to Play the AI Chip ShortageBy Thomas Hughes | April 14, 2026AEMD, HIND, SURG, and QNRX Company DescriptionsAethlon Medical NASDAQ:AEMD$2.34 +0.04 (+1.78%) As of 11:12 AM Eastern This is a fair market value price provided by Massive. Learn more.Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation. The company was incorporated in 1999 and is based in San Diego, California.Vyome NASDAQ:HIND$2.06 -0.04 (-2.05%) As of 11:11 AM Eastern This is a fair market value price provided by Massive. Learn more.ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.Quoin Pharmaceuticals NASDAQ:QNRX$6.32 -0.05 (-0.82%) As of 11:12 AM Eastern This is a fair market value price provided by Massive. Learn more.Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.SurgePays NASDAQ:SURG$0.54 -0.02 (-4.10%) As of 10:59 AM Eastern This is a fair market value price provided by Massive. Learn more.SurgePays, Inc., together with its subsidiaries, operates as a financial technology and telecom company in the United States. It operates through three segments: Mobile Virtual Network Operators, Comprehensive Platform Services, and Lead Generation. The company offers subsidized and non-subsidized mobile virtual network operators for internet connectivity through mobile broadband services to consumers; ACH banking relationships and fintech transactions platform to convenience stores; wireless top-up transactions and wireless product aggregation; and lead generation and case management solutions primarily to law firms in the mass tort industry, as well as call center activities. SurgePays, Inc. is headquartered in Bartlett, Tennessee. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
